1. Home
  2. Download Summary
New Try New Voice Based Search
×

Related Products

Summary Of Dabrafenib-API-Small Molecules

Download All File (.xls)

Chemical Name

Dabrafenib

CAS No.

1195765-45-7

Molecular Formula

C23H20F3N5O2S2

Innovator

Developer

Indication

Melanoma; Skin Cancer

Therapeutic Area

Oncology

Market Status

Launched

Approval Year

Patent Expiry

Detailed Summary of Dabrafenib API-Small Molecules

Chemxpert provides a consolidated intelligence snapshot for Dabrafenib API-Small Molecules, covering its technical profile, commercial footprint, global Dabrafenib supplier, Dabrafenib buyer and Dabrafenib manufacturer dynamics, and regulatory presence across key pharmaceutical markets.

Innovator and developer details, where available, are reflected based on verified disclosures within Chemxpert database.

Technical & Application Intelligence for Dabrafenib

Dabrafenib technical & application intelligence includes information on the industry and end-use applications, helping users understand its role across different formulation and therapeutic contexts. The data also covers routes of synthesis and manufacturing technologies, offering visibility into production methods, process variability, and technical complexity.

In addition, the mechanism of action describes how an API ingredient produces its therapeutic effect at the molecular or biological level in the body. This data supports scientific understanding, formulation development, and regulatory evaluation of Dabrafenib.

Chemxpert tracks the technical landscape of Dabrafenib across its manufacturing and application ecosystem.

Commercial & Market Indicators for Dabrafenib

Commercial & Market Indicators reflects the sales performance of Dabrafenib–based products across key pharmaceutical markets, including regulated regions such as the United States and the United Kingdom where available. It helps users understand regional demand trends, market maturity, and commercial presence of Dabrafenib in major drug markets.

  • Dabrafenib global market size is tracked in both volume (metric tonne) and value (USD)
  • Pricing intelligence includes average Dabrafenib API price benchmarks (USD/kg) derived from multiple verified sources
  • Regional Dabrafenib API sales performance including markets such as the US and UK is monitored where data is available

Global Supplier Landscape for Dabrafenib

Dabrafenib global supplier landscape provides intelligence on the API global supply ecosystem, helping users identify manufacturers, assess supply scale, and evaluate regulatory readiness.

  • Dabrafenib API Suppliers – Companies involved in the manufacturing or commercial supply of Dabrafenib
  • Supplying Volume – Indicator of quantity supplied used to assess production scale and capacity
  • Supplier Country Presence – Geographic distribution across countries
  • Supplier Regulatory Certifications – GMP, FDA and other approvals held by facilities
  • Dabrafenib API Verified Supplier Contact Information – Validated business contact details

Together, this supplier intelligence supports supplier discovery, qualification, diversification planning, and supply risk assessment. This dataset supports supplier qualification, diversification planning, and sourcing risk mitigation.

Buyer & Demand Intelligence for Dabrafenib

On the demand side, Dabrafenib API buyer supplier data intelligence tracks global procurement activities.

  • Total identified buyers across the globe
  • Total buying volume in metric tonne
  • Buyer presence across countries
  • Total number of certified buyers
  • Verified Dabrafenib API buyer contact records

This intelligence enables demand mapping, partner discovery, and market entry evaluation.

Get the detailed insight about Dabrafenib technical, commercial, supplier and buyer –Click here

Regulatory Filings & Market Authorization for Dabrafenib

Dabrafenib regulatory filings & market authorization provide a comprehensive view of approval status across global pharmaceutical markets.

  • US Drug Master File (US-DMF)
  • FDA National Drug Code (NDC)
  • Certificate of Suitability (CEP / COS)
  • EU API Registration
  • UK-MHRA Registration
  • REACH Registration
  • Written Confirmation

Asia-Pacific & Other Regional Filings

  • Japan Drug Master File (J-DMF)
  • Korea Drug Master File (K-DMF)
  • India Import Licence
  • China API Registration
  • Other regional registrations (Middle East, Africa, Latin America)

Finished Dosage Form (FDF) Market Authorization

  • North America
  • Europe
  • Oceania
  • Africa
  • Asia
  • South America

Geographic Distribution of Dabrafenib Counterparties

  • North America
  • Europe (Northern, Western, Southern, Eastern)
  • Asia
  • Africa
  • Middle East
  • South America
  • Oceania

Country-level counts are dynamically populated to reflect real-time database coverage.

Get the detailed insight about Dabrafenib Regulatory, Commercial and Geographic Distribution –Click here

Clinical, Patent & Compliance Intelligence for Dabrafenib

Clinical Trial Activity

Tracks ongoing and completed trials across the US, Europe, Asia-Pacific and India.

Patent & Exclusivity Landscape

  • Patent expiry
  • Market exclusivity
  • SPC extensions
  • Paragraph IV filings
  • Patent disputes & data protection

Certifications & Accreditations

  • US FDA
  • EU GMP
  • PMDA (Japan)
  • ANVISA (Brazil)
  • CDSCO, WHO-GMP, PIC/S

Regulatory Warnings & Compliance Signals

  • FDA warnings and recalls
  • Form 483 observations
  • Site inspection records
  • Country bans, price controls and essential medicine listings

Get detailed insight on Dabrafenib Clinical, Patent & Compliance –Click here

Biosimilar & Agrochemical Regulatory Status for Dabrafenib

Chemxpert tracks biosimilar and agrochemical regulatory activity related to Dabrafenib across global markets. A regulatory dashboard reflects filing and approval status in the US, Europe, Japan, India, China and other countries.

Get detailed Biosimilar & Agrochemical Regulatory Insight – Click here

Why Use Chemxpert for Dabrafenib API Intelligence?

Chemxpert combines supplier data, regulatory depth, commercial indicators, US DMF and compliance intelligence into a single continuously updated platform — helping pharmaceutical companies, buyers and regulators make faster and better-informed decisions.